Is there any association between nesfatin-1 and generalized anxiety disorder?

Temel Bulgular & Veri:Yöntem: Bu çalışmada 40 YAB’lu hasta ile yaş ve BMIile eşleştirilmiş 42 sağlıklı kontrol’un plasma nesfatin-1düzeyleri ölçüldü.

💡

Sonuç & Katkı:Bulgular: Hasta ve kontrol grupları arasında nesfatin-1düzeyinde anlamlı bir farklılık yoktur.

🔬Tür:Araştırma Makalesi

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Alan Parametreleri

Özet

Amaç: Bu çalışmanın amacı yaygın anksiyete bozukluğu(YAB)’nun patogenezinde nesfatin-1’in olası rolünü araştırmaktır. Yöntem: Bu çalışmada 40 YAB’lu hasta ile yaş ve BMIile eşleştirilmiş 42 sağlıklı kontrol’un plasma nesfatin-1düzeyleri ölçüldü. Anksiyete şiddeti Hamilton Anksiyete Derecelendirme Ölçeği (HAM-A) ile değerlendirildi. Bulgular: Hasta ve kontrol grupları arasında nesfatin-1düzeyinde anlamlı bir farklılık yoktur. Ortalama serumnesfatin-1 düzeyi yaş, hastalık süresi, BMI ve HAM-Askoru ile korelasyon göstermiyordu. Sonuç: Sonuçlarımız YAB‘nun nesfatin-1 ile ilişkiliolduğunu desteklemiyor.

Abstract

Objective: The aim of the present study was to find out the possible role of nesfatin-1 in the pathogenesis of generalized anxiety disorder (GAD). Methods: In this study, we measured plasma nesfatin-1 levels in 40 GAD patients and 42 controls that were matched by age and BMI. The severity of anxiety was evaluated with the Hamilton Anxiety Rating Scale (HAM-A). Results: There was no statistically significant difference in the nesfatin-1 levels between patient and control groups. The mean serum nesfatin-1 level did not show any correlation with age, duration of illness, BMI, HAM-A scores in the patient and control groups. Conclusion: Our results do not support that nesfatin-1 is associated with GAD.

🔖

Bu Makaleye Atıf Yap

BAHCECİ, B., BAGCIOGLU, E., HELVACI, F. C., BAHCECİ, I., GONUL, Y., HOCAOGLU, C., DİLEK, A. R. (2022). Is there any association between nesfatin-1 and generalized anxiety disorder?. Klinik Psikofarmakoloji Bülteni, Cilt: 24 - Sayı: 1, 55–58. https://ajindex.com/articles/574018

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, (4th ed, text revision). Washington, D:American Psychiatric Association, 2000
Connor KM, Davidson JR. Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. Biol Psychiatry 1998;44(12):1286-94. [CrossRef] 3. Korpi ER, Grunder G, Luddens H. Drug interactions at GABA (A) receptors. Prog Neurobiol 2002;67(2):113-59. [CrossRef] 4. Strawn JR, Wehry AM, Delbello MP, Rynn MA, Strakowski S. Establishing the neurobiologic basis of treatment in children and adolescents with generalized anxiety disorder. Depress Anxiety 2012;29(4):328-39. [CrossRef] 5. Lohoff FW, Aquino TD, Narasimhan S, Multani PK, Etemad B, Rickels K. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J 2013;13(1):21-6. [CrossRef] 6. Iny LJ, Pecknold J, Suranyi-Cadotte BE, Bernier B, Luthe L, Nair NP, et al. Studies of a neurochemical link between depression, anxiety, and stress from (3H) imipramine and (3 H) paroxetine binding on human plateletes. Biol Psychiatry 1994;36(5):281-91. [CrossRef] 7. Garvey MJ, Noyes R Jr, Woodman C, Laukes C. The association of urinary 5-hydroxyindoleacetic acid and vanillylmandelic acid in patients with generalized anxiety. Neuropsychobiolgy 1995;31(1):6-9. [CrossRef] 8. Brawman-Mintzer O, Lydiard RB, Bradwejn J, Villarreal G, Knapp R, Emmanuel N, et al. Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Am j Psychiatry 1997;154(5):700-2
Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006;443(7112):709-12. [CrossRef] 10. Palasz A, Krzystanek M, Worthington J, Czajkowska B, Kostro K, Wiaderkiewicz et al. Nesfatin-1, a unique regulatory neuropeptide of the brain. Neuropeptides 2012;46(3):105- 12. [CrossRef] 11. Price TO,Samson WK, Niehoff ML, Banks WA. Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides 2007;28(12):2372-81. [CrossRef] 12. Merali Z, Cayer C, Kent P, Anisman H. Nesfatin-1 increases anxiety and fear related behaviors in the rat. Psychopharmacology (Berl) 2008;201(1):115-23. [CrossRef] 13. Ari M, Ozturk OH, Bez Y, Oktar S, Erduran D. High plasma nesfatin-1 level in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(2):497-